European Life Science Investor LSP Raises $1+ B Fund: A First for Europe

European Life Science Investor LSP Raises $1+ B Fund: A First for Europe

LSP just achieved a milestone becoming the first life science-focused investment fund to hit the $1 billion level with the latest fund LSP 7. With a goal of reaching over $3 billion, LSP 7’s investors range from pension funds and insurance companies to wealth managers and government funds.

TrialSite Investor Watch provides a brief breakdown of this recent news.

What is LSP 7?

One of Europe’s largest healthcare investment firms, LSP 7 goes back 30 years with an emphasis on high-quality healthcare investments with substantial societal impact.

With a dedicated experienced team of investment professionals, the investment house seeks out the “smartest inventors with ideas that truly make a difference.”

Does LSP 7 have pharmaceutical company investors?

Yes.

Where are they located?

Amsterdam, Munich, and Boston

What will LSP 7 investor in?

15 to 20 innovative drug development or medical technology companies mostly in Europe.  This particular fund has already completed three investments.

What has this fund put money in thus far?

Egle Therapeutics, a French biotech developing T-regulatory cell therapies for oncology and auto-immune diseasesUndisclos...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee